Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)

References

• Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–120.
   PubMedGoogle Scholar
• Cohen LB, Nanau RM, Delzor F, et al. Biologic therapies in inflammatory bowel disease. Transl Res. 2014;163(6):533–556. DOI:10.1016/j.trsl.2014.01.002
   PubMed Web of Science ®Google Scholar
• Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade(®) (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–178.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry; 2015 [cited 2020 15 Feb]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
   Google Scholar
• US Food and Drug Administration (FDA). Patient materials, biosimilars; 2019 [cited 2020 5 Mar]. Available from: https://www.fda.gov/drugs/biosimilars/patient-materials
   Google Scholar
• Celltrion Healthcare. Remsima®; 2020 [cited 2020 19 Feb]. Available from: https://www.celltrionhealthcare.com/en-us/products/product?pkey=5
   Google Scholar
• GaBi online (Generics and Biosimilars Initiative). Biosimilars of infliximab; 2015 [cited 2020 10 Dec]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab
   Google Scholar
• Gabbani T, Deiana S, Annese V. CT-P13: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:1653–1661.
   PubMed Web of Science ®Google Scholar
• Hospira (a Pfizer Company). Inflectra (infliximab-dyyb) US prescribing information; 2016 [cited 2020 18 Oct]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf
   Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612. DOI:10.1136/annrheumdis-2012-203091
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620. DOI:10.1136/annrheumdis-2012-203090
   PubMed Web of Science ®Google Scholar
• Ye B, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet (London, England). 2019;393:1699–1707.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Baek K, Lee S, et al. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34(4):513–528. DOI:10.1007/s40259-020-00421-2
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2013; Inflectra (infliximab): summary of product characteristics [cited 2020 18 Dec]. Available from: https://www.ema.europa.eu/en/documents/product-information/inflectra-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Remicade (infliximab): summary of product characteristics; 2009 [cited 2020 10 Dec]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
   Google Scholar
• D’Haens G, Reinisch W, Colombel JF, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade®] or conventional therapy. J Crohns Colitis. 2017;11(6):680–689. DOI:10.1093/ecco-jcc/jjw221
   PubMed Web of Science ®Google Scholar
• Panes J, Lindsay JO, Teich N, et al. Five-year safety data from OPUS, a European observational safety registry for adults with ulcerative colitis treated with originator infliximab [Remicade®] or conventional therapy. J Crohns Colitis. 2019;13(9):1148–1157. DOI:10.1093/ecco-jcc/jjz048
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Remsima: ePAR - risk management plan - summary; 2019 [cited 2020 10 Dec]. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/remsima-epar-risk-management-plan-summary_en.pdf
   Google Scholar
• Abraham B, Eksteen B, Nedd K, et al. Impact of Infliximab-dyyb (Infliximab Biosimilar) on clinical and patient-reported outcomes: 1-year follow-up results from an observational real-world study among patients with inflammatory bowel disease in the US and Canada (the ONWARD Study). Adv Ther. 2022;39(5):2109–2127. DOI:10.1007/s12325-022-02104-6
   PubMed Web of Science ®Google Scholar
• Gonczi L, Gecse KB, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017;23(11):1908–1915. DOI:10.1097/MIB.0000000000001237
   PubMed Web of Science ®Google Scholar
• Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–1057. DOI:10.1111/apt.13990
   PubMed Web of Science ®Google Scholar
• Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99–113. DOI:10.1007/s40265-020-01256-5
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Goll GL, Sexton J, et al. Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials. BioDrugs. 2020;34(5):681–694. DOI:10.1007/s40259-020-00438-7
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. DOI:10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–767.
   PubMed Web of Science ®Google Scholar
• Ungar B, Ben-Shatach Z, Ben-Haim G, et al. Infliximab therapy intensification upon loss of response: is there an optimal trough level? Dig Liver Dis. 2019;51(8):1106–1111. DOI:10.1016/j.dld.2019.02.013
   PubMedGoogle Scholar
• Guerra Veloz MF, Arguelles-Arias F, Castro Laria L, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(46):5288–5296. DOI:10.3748/wjg.v24.i46.5288
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
   PubMed Web of Science ®Google Scholar